Which has stronger valuation & earnings, AAPG or PCVX?

Ascentage Pharma Group International has higher revenue and earnings than Vaxcyte. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 20.78 -$177.71M N/A N/A Vaxcyte N/A N/A -$766.63M -$6.88 N/A

Is AAPG or PCVX more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Vaxcyte N/A -32.51% -29.51%

Does the media favor AAPG or PCVX?

In the previous week, Vaxcyte had 2 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 5 mentions for Vaxcyte and 3 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 0.52 beat Vaxcyte's score of 0.21 indicating that Ascentage Pharma Group International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascentage Pharma Group International 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, IMVT or AAPG?

Ascentage Pharma Group International has higher revenue and earnings than Immunovant. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.78 N/A Ascentage Pharma Group International $82.10M 20.78 -$177.71M N/A N/A

Is IMVT or AAPG more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% Ascentage Pharma Group International N/A N/A N/A

Which has stronger earnings & valuation, KYMR or AAPG?

Ascentage Pharma Group International has higher revenue and earnings than Kymera Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kymera Therapeutics $39.21M 156.53 -$311.35M -$3.57 N/A Ascentage Pharma Group International $82.10M 20.78 -$177.71M N/A N/A

Which has preferable valuation & earnings, AAPG or LNTH?

Lantheus has higher revenue and earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 20.78 -$177.71M N/A N/A Lantheus $1.54B 4.34 $233.56M $4.15 24.78

Does the media favor AAPG or LNTH?

In the previous week, Lantheus had 1 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 4 mentions for Lantheus and 3 mentions for Ascentage Pharma Group International. Lantheus' average media sentiment score of 0.54 beat Ascentage Pharma Group International's score of 0.52 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascentage Pharma Group International 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, AAPG or PTGX?

Protagonist Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 20.78 -$177.71M N/A N/A Protagonist Therapeutics $46.02M 143.64 -$130.15M -$1.81 N/A

Ascentage Pharma Group International (AAPG) Competitors

$18.28 +0.41 (+2.29%)

Closing price 03:59 PM Eastern

Extended Trading

$18.28 0.00 (0.00%)

As of 06:58 PM Eastern

Compare

AAPG vs. PCVX, IMVT, KYMR, LNTH, and PTGX

Should you buy Ascentage Pharma Group International stock or one of its competitors? MarketBeat compares Ascentage Pharma Group International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ascentage Pharma Group International include Vaxcyte (PCVX), Immunovant (IMVT), Kymera Therapeutics (KYMR), Lantheus (LNTH), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

How does Ascentage Pharma Group International compare to Vaxcyte?

Ascentage Pharma Group International (NASDAQ:AAPG) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Ascentage Pharma Group International presently has a consensus target price of $46.67, suggesting a potential upside of 155.29%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 76.37%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, equities research analysts plainly believe Ascentage Pharma Group International is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Ascentage Pharma Group International has higher revenue and earnings than Vaxcyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	20.78	-$177.71M	N/A	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Ascentage Pharma Group International has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

Ascentage Pharma Group International's return on equity of 0.00% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Vaxcyte	N/A	-32.51%	-29.51%

In the previous week, Vaxcyte had 2 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 5 mentions for Vaxcyte and 3 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 0.52 beat Vaxcyte's score of 0.21 indicating that Ascentage Pharma Group International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.8% of Vaxcyte shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Ascentage Pharma Group International beats Vaxcyte on 8 of the 12 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Immunovant has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of -0.05, indicating that its stock price is 105% less volatile than the broader market.

47.1% of Immunovant shares are held by institutional investors. 1.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ascentage Pharma Group International's return on equity of 0.00% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Ascentage Pharma Group International	N/A	N/A	N/A

In the previous week, Immunovant had 3 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 6 mentions for Immunovant and 3 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 0.52 beat Immunovant's score of 0.43 indicating that Ascentage Pharma Group International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant presently has a consensus price target of $37.33, suggesting a potential upside of 14.27%. Ascentage Pharma Group International has a consensus price target of $46.67, suggesting a potential upside of 155.29%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, analysts plainly believe Ascentage Pharma Group International is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25

Ascentage Pharma Group International has higher revenue and earnings than Immunovant.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Ascentage Pharma Group International	$82.10M	20.78	-$177.71M	N/A	N/A

Summary

Ascentage Pharma Group International beats Immunovant on 8 of the 12 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Ascentage Pharma Group International has higher revenue and earnings than Kymera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	156.53	-$311.35M	-$3.57	N/A
Ascentage Pharma Group International	$82.10M	20.78	-$177.71M	N/A	N/A

Kymera Therapeutics presently has a consensus price target of $118.10, suggesting a potential upside of 58.28%. Ascentage Pharma Group International has a consensus price target of $46.67, suggesting a potential upside of 155.29%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts plainly believe Ascentage Pharma Group International is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25

Ascentage Pharma Group International has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Ascentage Pharma Group International's return on equity of 0.00% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Ascentage Pharma Group International	N/A	N/A	N/A

In the previous week, Kymera Therapeutics had 1 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 4 mentions for Kymera Therapeutics and 3 mentions for Ascentage Pharma Group International. Kymera Therapeutics' average media sentiment score of 1.39 beat Ascentage Pharma Group International's score of 0.52 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kymera Therapeutics has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market.

Summary

Ascentage Pharma Group International beats Kymera Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Lantheus?

Ascentage Pharma Group International (NASDAQ:AAPG) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Ascentage Pharma Group International presently has a consensus target price of $46.67, indicating a potential upside of 155.29%. Lantheus has a consensus target price of $101.86, indicating a potential downside of 0.94%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts clearly believe Ascentage Pharma Group International is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

99.1% of Lantheus shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Lantheus has a net margin of 18.05% compared to Ascentage Pharma Group International's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Ascentage Pharma Group International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Lantheus	18.05%	29.32%	15.00%

Ascentage Pharma Group International has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market.

In the previous week, Lantheus had 1 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 4 mentions for Lantheus and 3 mentions for Ascentage Pharma Group International. Lantheus' average media sentiment score of 0.54 beat Ascentage Pharma Group International's score of 0.52 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has higher revenue and earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	20.78	-$177.71M	N/A	N/A
Lantheus	$1.54B	4.34	$233.56M	$4.15	24.78

Summary

Lantheus beats Ascentage Pharma Group International on 11 of the 15 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Protagonist Therapeutics?

Ascentage Pharma Group International (NASDAQ:AAPG) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Ascentage Pharma Group International has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Ascentage Pharma Group International's return on equity of 0.00% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Protagonist Therapeutics had 4 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 7 mentions for Protagonist Therapeutics and 3 mentions for Ascentage Pharma Group International. Protagonist Therapeutics' average media sentiment score of 0.72 beat Ascentage Pharma Group International's score of 0.52 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascentage Pharma Group International currently has a consensus price target of $46.67, indicating a potential upside of 155.29%. Protagonist Therapeutics has a consensus price target of $115.21, indicating a potential upside of 12.09%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, research analysts clearly believe Ascentage Pharma Group International is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Protagonist Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	20.78	-$177.71M	N/A	N/A
Protagonist Therapeutics	$46.02M	143.64	-$130.15M	-$1.81	N/A

Ascentage Pharma Group International has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market.

Summary

Protagonist Therapeutics beats Ascentage Pharma Group International on 8 of the 15 factors compared between the two stocks.

Get Ascentage Pharma Group International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AAPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AAPG vs. The Competition

Export

Metric	Ascentage Pharma Group International	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.67B	$3.34B	$6.44B	$12.46B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	N/A	18.78	23.87	24.36
Price / Sales	20.78	320.80	521.52	117.01
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	8.96	6.80	9.99	6.73
Net Income	-$177.71M	$24.09M	$3.56B	$337.03M
7 Day Performance	-9.46%	-2.56%	-0.89%	0.09%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-35.38%	48.90%	28.76%	33.98%

Ascentage Pharma Group International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AAPG Ascentage Pharma Group International	3.4043 of 5 stars	$18.28 +2.3%	$46.67 +155.3%	-35.6%	$1.67B	$82.10M	N/A	600	Gap Up
PCVX Vaxcyte	2.775 of 5 stars	$51.40 flat	$86.00 +67.3%	+35.4%	$7.42B	N/A	N/A	160	Insider Trade
IMVT Immunovant	2.09 of 5 stars	$33.30 flat	$37.33 +12.1%	+101.7%	$6.84B	N/A	N/A	120
KYMR Kymera Therapeutics	2.4398 of 5 stars	$81.42 flat	$118.10 +45.0%	+67.9%	$6.70B	$39.21M	N/A	170
LNTH Lantheus	2.0809 of 5 stars	$99.30 flat	$101.86 +2.6%	+29.0%	$6.47B	$1.54B	23.93	1,193

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AAPG) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ascentage Pharma Group International (AAPG) Competitors

AAPG vs. PCVX, IMVT, KYMR, LNTH, and PTGX

How does Ascentage Pharma Group International compare to Vaxcyte?

Summary

How does Ascentage Pharma Group International compare to Immunovant?

Summary

How does Ascentage Pharma Group International compare to Kymera Therapeutics?

Summary

How does Ascentage Pharma Group International compare to Lantheus?

Summary

How does Ascentage Pharma Group International compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG vs. The Competition

Ascentage Pharma Group International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ascentage Pharma Group International (AAPG) Competitors

AAPG vs. PCVX, IMVT, KYMR, LNTH, and PTGX

How does Ascentage Pharma Group International compare to Vaxcyte?

Do analysts rate AAPG or PCVX?

Which has stronger valuation & earnings, AAPG or PCVX?

Which has more risk & volatility, AAPG or PCVX?

Is AAPG or PCVX more profitable?

Does the media favor AAPG or PCVX?

Do insiders & institutionals hold more shares of AAPG or PCVX?

Summary

How does Ascentage Pharma Group International compare to Immunovant?

Which has more risk and volatility, IMVT or AAPG?

Do insiders and institutionals have more ownership in IMVT or AAPG?

Is IMVT or AAPG more profitable?

Does the media prefer IMVT or AAPG?

Do analysts rate IMVT or AAPG?

Which has stronger earnings and valuation, IMVT or AAPG?

Summary

How does Ascentage Pharma Group International compare to Kymera Therapeutics?

Which has stronger earnings & valuation, KYMR or AAPG?

Do analysts prefer KYMR or AAPG?

Is KYMR or AAPG more profitable?

Does the media favor KYMR or AAPG?

Which has more risk & volatility, KYMR or AAPG?

Summary

How does Ascentage Pharma Group International compare to Lantheus?

Do analysts prefer AAPG or LNTH?

Do insiders and institutionals believe in AAPG or LNTH?

Is AAPG or LNTH more profitable?

Which has more volatility and risk, AAPG or LNTH?

Does the media favor AAPG or LNTH?

Which has preferable valuation & earnings, AAPG or LNTH?

Summary

How does Ascentage Pharma Group International compare to Protagonist Therapeutics?

Is AAPG or PTGX more profitable?

Do institutionals & insiders believe in AAPG or PTGX?

Does the media prefer AAPG or PTGX?

Do analysts recommend AAPG or PTGX?

Which has stronger earnings & valuation, AAPG or PTGX?

Which has more volatility and risk, AAPG or PTGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG vs. The Competition

Ascentage Pharma Group International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools